Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines by Kroep, J R et al.
Gemcitabine and paclitaxel are among the most active agents in
the treatment of non-small-cell lung cancer (Giaccone, 1995;
Rajkumar and Adjei, 1998). The rationale for the gemcita-
bine–paclitaxel combination is supported by their different mecha-
nisms of action and the partially non-overlapping toxicities
(Rowinsky et al, 1995; Van Moorsel et al, 1997). Understanding of
possible drug–drug interactions and cell cycle disturbances
induced by gemcitabine and paclitaxel may help designing
appropriate treatment schedules.
Gemcitabine, a deoxycytidine analogue, is phosphorylated to its
monophosphate by deoxycytidine kinase (dCK) and subsequently
by nucleotide kinases to its active metabolite, gemcitabine triphos-
phate (dFdCTP) (Heinemann et al, 1988; Ruiz van Haperen et al,
1994). dFdCTP accumulation was clearly correlated to its cyto-
toxicity (Van Moorsel et al, 2000). Several self-potentiating mech-
anisms have been described (Heineman et al, 1995; Peters and
Ackland, 1996), which may enhance the incorporation of dFdCTP
into the DNA and possibly also into RNA. Gemcitabine induces a
G0/G1 and S phase arrest (Hertel et al, 1990; Tolis et al, 1999) and
triggers apoptotis in human leukaemia (Bouffard and Momparler,
1995; Huang and Plunkett, 1995) and solid tumour cells (Tolis
et al, 1999).
Paclitaxel acts as a mitotic spindle poison by blocking eukary-
otic cells in the G2/M mitotic phase of the cell cycle (Schiff et al,
1979; Rowinsky et al, 1988). Paclitaxel promotes microtubule
assembly and stabilization by preventing depolymerization,
leading to inhibition of cell proliferation and induction of cell
death (Schiff et al, 1979). At low concentrations paclitaxel
inhibited mitosis by altering microtubule dynamics (Jordan et al,
1993), resulting in cells with abnormal size and DNA content
causing cell death (Torres and Horwitz, 1998). At higher concen-
trations, paclitaxel caused formation of stable bundles of micro-
tubules and increased microtubule polymer mass (Jordan et al,
1993), resulting in G2/M phase arrest and apoptosis (Torres and
Horwitz, 1998).
Because of the different effects of each drug on cellular metabo-
lism and cell cycle distribution, sequential drug administration
may result in potentiation of both single agents. Gemcitabine
showed synergism/additivity when combined with cisplatin,
etoposide, mitomycin C and topotecan (Van Moorsel et al, 1999;
Tolis et al, 1999). However, previously, the combination with
paclitaxel was reported to be less than additive (Theodossiou et al,
1998). For paclitaxel, a marked resistance has been shown when
cells are not cycling (Hahn et al, 1993; Theodossiou et al, 1998).
Combinations of paclitaxel with alkylators or cisplatin were
sequence dependent, showing superior cytotoxicity when pacli-
taxel was administered first (Rowinsky et al, 1993; Liebmann 
et al, 1994). In patients, we recently demonstrated that paclitaxel
increased the accumulation of dFdCTP (Kroep et al, 1999),
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cells. Paclitaxel did not affect deoxycytidine kinase levels, but ribonucleotide levels increased possibly explaining the increase in dFdCTP.
Paclitaxel did not affect gemcitabine incorporation into DNA, but seemed to increase incorporation into RNA. Gemcitabine almost completely
inhibited DNA synthesis in both cell lines (70–89%), while paclitaxel had a minor effect and did not increase that of gemcitabine. In conclusion,
various gemcitabine–paclitaxel combinations did not show sequence dependent cytotoxic effects; all combinations were not more than
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doi: 10.1054/ bjoc.2000.1399, available online at http://www.idealibrary.com on indicating that paclitaxel administration prior to gemcitabine
might be favourable, as compared to its reverse sequence.
To elucidate potential mechanisms for paclitaxel and gem-
citabine interactions we investigated metabolic drug–drug inter-
actions and used different sequences to determine the role of cell
cycle effects on cytotoxicity of the combinations.
MATERIAL AND METHODS
Chemicals
Paclitaxel (Taxol®; Bristol-MyersSquibb, Princeton, NY) was
dissolved in 100% ethanol. Gemcitabine (Gemzar®; 2′ ,2′ -difluoro-
2′ -deoxycytidine; dFdC) and (5-3H)-gemcitabine (16.7 Ci/mmol)
were a kind gift of Eli Lilly Inc., Indianapolis, USA and were
dissolved in phosphate buffered saline (PBS) and 50% (v/v)
ethanol, respectively. (8-3H)-2-chlorodeoxyadenosine (3H-CdA,
24.2 Ci/mmol) was purchased from Moravek Brea, CA, USA,
(2-14C)-Thymidine (14C-TdR, 59.7 Ci/mmol) from Dupont de
Nemours NEND, Boston, MA, USA and (5-3H)-uridine (3H-UR,
27.0 Ci/mmol) from Amersham International, Buckinghamshire,
England. All other chemicals were of analytical grade.
Cell culture
The NSCLC cell lines Lewis Lung carcinoma (LL, murine)
[Mayo, 1972], H460 (NCl-H460, human, wild-type-p53) and
H322 (NCl-H322, human, mutant-p53) (Winter et al, 1992) were
grown in monolayers and maintained in exponential growth in
RPMI 1640 supplemented with 10% heat-inactivated fetal calf
serum (FCS) (GIBCO, Paisley, UK) and 250 ng/ml gentamycin at
37° C at 5% carbon dioxide. Cell doubling times were 26 h, 18 h
and 40 h under these conditions, respectively.
Growth inhibition assay
Antiproliferative effects were analysed by the sulforhodamine B
assay as described previously (Keepers et al, 1991). Briefly, cells
were seeded in triplicate in 96-well flat bottom plates (Costar,
Cambridge, MA, USA): LL, 5000 cells/well; H460, 5000
cells/well and H322, 20 000 cells/well. After 24 h drugs were
added with a gemcitabine:paclitaxel ratio of 1:3, based on the
obtained IC-50 values. Cell lines were exposed for 4, 24 and 72 h,
with a total culture time of 96 h. In H460 cells, sequential drug
exposure, gemcitabine 4 and 24 h before paclitaxel and the reverse
sequences, were also tested.
In order to quantify the degree of drug interaction, multiple drug
effect analysis was performed based on that described by Chou
and Talalay (Chou and Talalay, 1984) using computer software of
Chou (CalcuSyn v 1.1.1, Biosoft 1996, Cambridge, UK). Results
were expressed as mutually non-exclusive combination index (CI)
values for every fraction affected (FA), while for the final evalua-
tion we used the averaged CI at 0.5, 0.75, 0.90, and 0.95 FA, repre-
senting relevant growth inhibition values. In the current software
package (Calcusyn), the classification for the effect is as follows:
CI < 0.3 = highly synergistic; 0.3–0.7 = synergistic; 0.7–0.9 =
moderate to slight synergistic; 0.9–1.1 = nearly additive; 1.1–
1.45 = slight to moderate antagonistic, 1.45–3.3 = antagonistic;
>3.3 = strong antagonistic.
Flow cytometry
To determine the cell cycle events following different gemcita-
bine–paclitaxel combinations, flow cytometric measurement of
cellular DNA content using propidium iodide (PI) (Sigma Aldrich,
Deisenhofen, Germany) was performed as described previously
(Tolis et al, 1999). Briefly, H460 and H322 cells were exposed to
gemcitabine and paclitaxel alone and simultaneously at IC-50 and
10 × IC-50 concentrations. At 4, 24, 48 and 72 h after start of drug
exposure, cells (including the floating cells) were harvested, resus-
pended in PI solution and analysed on a FACScan flow cytometer
(Beckton Dickinson, Mountain View, CA, USA), using the cell fit
program (CellFit™, Becton Dickinson, San Jose, CA). Cells
which were less intensively stained than G1 cells (sub-G1 cells),
were considered apoptotic cells. The flow rate was at about
200–500 nuclei/s and at least 20 × 104 cells of each sample were
analysed. Measurements were performed under the same instru-
mental settings. Based on these experiments, the 4 and 24 h time-
intervals were chosen for sequential drug exposure. These latter
cultures were incubated for 28, 48 and 72 h.
The effect of paclitaxel on dCK activity
To determine a possible influence of paclitaxel on dCK activity,
H460 and H322 cells were exposed to paclitaxel at IC-50 for 24 h,
after which cells were harvested as described previously (Ruiz van
Haperen et al, 1996), and stored at –80° C until analysis. dCK was
assayed essentially as described previously (Ruiz van Haperen et
al, 1996) but utilizing (8- 3H)-2-chlorodeoxyadenosine (3H-CdA;
50 µ M; 0.16 µ Ci/nmol) as the substrate (Spasokoukotskaja et al,
1995). Enzyme activities were expressed as nmol product formed
per h per 106 cells (nmol/h/106 cells).
dFdCTP accumulation
To determine the influence of paclitaxel on the dFdCTP accumula-
tion, cells were seeded in 2 ml 6-well plates (H460, 2.5 × 105
cells/well; H322, 5 × 105 cells/well). After 24 h, cells were
exposed to gemcitabine at 0.1 and 1.0 µ M with or without pacli-
taxel at 0.033 and 0.33 µ M, respectively, for 24 h at 37° C. Cells
were harvested, nucleotides were extracted and dFdCTP and
nucleotides were analysed by HPLC as described previously (Ruiz
van Haperen et al, 1994).
Determination of the influence of paclitaxel on
gemcitabine incorporation
Incorporation of 3H-gemcitabine into DNA and RNA was
performed essentially as described previously (Van Moorsel et al,
1999). Briefly, cells were plated (1 × 104 H460 and 2 × 104 H322
cells) into 96-well filter bottom plates (Multiscreen® Filtration
system, 0.22 µ m Hydrophilic Low Protein Binding Durapore®
membrane, Millipore, Ettenleur, The Netherlands), and after 24 h
exposed to (5-3H)-gemcitabine 0.05 µ M final concentration
(21 Ci/mmol) with or without 0.17 or 0.017 µ M paclitaxel for 4
and 24 h at 37° C. Incorporation into DNA was determined by
adding 20 µ l RNAase A/T1 (500 U/ml; DNAase-free) and 80 µ l
PBS to one part of the wells followed by an incubation for 30 min
at 37° C. RNA incorporation was determined by subtracting the
DNA incorporation from the total incorporation. Inhibition of
DNA and RNA synthesis was measured in separate cultures
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(59.7 mCi/mmol; 5.6 µ M) and 3H-UR (27 Ci/mmol; 165 nM) for
the last 2 h of the assay.
RESULTS
Growth inhibition of gemcitabine and paclitaxel
Table 1 summarizes the sensitivities of the three NSCLC cell lines
to gemcitabine and paclitaxel. H460 cells were most sensitive to
gemcitabine, but were the least sensitive to paclitaxel after 24 and
72 h exposure. For both drugs IC-50 values after 72 h exposure
were lower than after shorter incubation times. Based on these
data, combination ratios were designed for simultaneous and
sequential combinations. Representative growth inhibition curves
in LL cells are shown in Fig. 1a.
Fig. 1b depicts the multiple drug-effect analysis for LL cells.
The CI/FA plot after 4 h drug exposure showed antagonism at the
lower FA, while at the more relevant FA (≥ 50%) an additive effect
was observed. The average CI values for gemcitabine and pacli-
taxel combined in LL, H460 and H322 cells are summarized in
Table 2. Simultaneous drug administration resulted in an additive
to antagonistic effect, represented by a CI ranging from 1.0 to 2.6.
Based on the cell cycle effects of both gemcitabine and paclitaxel
(see next section) we reasoned that sequential drug treatment
would exploit cell cycle arrest caused by one drug in order to
increase sensitivity to the other drug. These schedule dependent
drug interactions were investigated in the H460 cell line (Table 2).
For all schedules the effect was not more than additive.
Effects on the cell cycle
DNA flow cytometry studies were performed to determine the effect
of different gemcitabine–paclitaxel combinations on the cell cycle
distribution and to determine whether these could be used to opti-
mize scheduling. Gemcitabine at IC-50 concentrations caused accu-
mulation of cells in the S-phase, while at 10 × IC-50 concentrations
(Fig. 2) cells predominantly accumulated in G0/G1 phase. Paclitaxel
at IC-50 concentrations increased accumulation in the G2/M phase,
which was maximal within 24 h and more pronounced at 10 × IC-50
values (Fig. 2). At 24 h, simultaneous exposure to gemcitabine and
paclitaxel resulted in an accumulation of the cells in the S phase of
the cell cycle at the 10 × IC-50 concentrations (45%).
For the study of sequential applications, gemcitabine was added
4 and 24 h prior to or after paclitaxel and cultures were incubated
up to 28, 48 and 72 h (Table 3). Exposure to gemcitabine 4 or 24 h
Sequence dependent effect of paclitaxel 1071
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Table 1 Sensitivity of NSCLC cell lines for gemcitabine and paclitaxel
Cell line IC-50 Gemcitabine (nM) IC-50 Paclitaxel (nM)
4h 2 4h 7 2h 4h 2 4h 7 2h
H460 160 ± 7 28 ± 1 4.3 ± 3.7 680 ± 169 141 ± 60 88 ± 32
H322 708 ± 335 420 ± 201 25 ± 13 1900 ± 893 14 ± 41 1   ± 6
LL 800 ± 100 27 ± 7 13 ± 4 410 ± 90 26 ± 12 5.6 ± 3.0
The IC-50 is defined as the concentration causing 50% growth inhibition in treated cells after 4, 24 and 72 h exposure to each drug alone,
followed by 68, 48 and 0 h incubation in drug free medium, respectively, as compared to control cells. Values are means ± SEM of at least
three separate experiments.
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Figure 1 (A) Representative growth inhibition curves of gemcitabine (  ) and paclitaxel (  ) alone and in combination (  ) in LL cells. Cells were exposed to the
drugs for 4 h followed by 68 h drug free medium, and growth inhibition was determined after 72 h by the sulforhodamine B assay. (B) Multiple drug effect
analysis of the interaction between gemcitabine and paclitaxel in LL cells exposed for 4 h (  ), 24 h (  ) and 72 h (  ) to the combination. Results are th
mean ± SEM of at least 3 experiments
Bprior to paclitaxel resulted in an increased G2/M arrest after 28 h
as compared to exposure to gemcitabine alone, comparable to that
of paclitaxel alone. For the reversed sequences, the second drug,
gemcitabine, also dominated the cell cycle effect at 28 h.
However, after 72 h, the first drug seemed to dominate for both
sequences, with a significantly different cell cycle distribution for
the 24 h time interval (Table 3). From 24 until 72 h the fraction of
arrested cells decreased rapidly, while the fraction of dead cells
(either apoptotic or necrotic cells) increased proportionally.
Cell death
Flow cytometric analysis of cell death using PI staining permits
simple measurement of apoptosis (Nicoletti et al, 1991).
Previously, we compared three methods for assessment of the
apoptotic index: analysis of morphological changes using May-
Grünwald-Giemsa (MGG) staining, the TUNEL assay and FACS
analysis (Tolis et al, 1999). Since relative effects were compar-
able, we used FACS analysis to determine the sub-G1 peak for
assessment of the influence of drug scheduling on apoptotis. Basal
levels of apoptosis ranged from 2.5 ± 0.4% after 4 h to 4.4 ± 1.5%
after 72 h, which increased after treatment (Fig. 3). Apoptotic cell
death at 72 h was significantly higher (P = 0.05) when paclitaxel
was added 24 h prior to gemcitabine (20% ± 4) as compared to the
reverse sequence (12% ± 5). Combined drug treatment also
induced necrosis time- and concentration-dependently; after 72 h
ranging from 35 to 40% at IC-50 concentrations and from 67 to
72% at 10 × IC50 concentrations. No schedule dependent differ-
ences were observed.
Effect on dFdCTP accumulation and normal nucleotide
pools
In mononuclear cells of patients, we previously observed a
paclitaxel induced increase of dFdCTP, the main metabolite of
gemcitabine (Kroep et al, 1999). Therefore, we measured the
accumulation of dFdCTP in NSCLC cells. In H460 cells, 0.03 µ M
paclitaxel significantly (P = 0.035) increased dFdCTP accumulation
from 28 ± 8 to 62 ± 2 pmol/106 cells after exposure to 0.1 µ M
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Table 2 Evaluation of synergism/antagonism with the multiple drugs effect
analysis
Drug exposure LL H460 H322
Simultaneous
4 h 1.4 ± 0.4 2.6 ± 1.0 1.4 ± 0.4
24 h 1.0 ± 0.1 1.8 ± 0.3 2.0 ± 0.8
72 h 1.5 ± 0.3 1.5 ± 0.3 1.1 ± 0.8
Sequentially
Gem > 4 hr > Tax 1.5 ± 0.2
Gem > 24 hr > Tax 1.3 ± 0.2
Tax > 4 hr < Gem 1.6 ± 0.3
Tax > 24 hr > Gem 1.0 ± 0.1
Mean combination index (CI) values after exposure to gemcitabine and
paclitaxel simultaneously for 4, 24 and 72 h in LL, H460 and H322 cells and
sequentially, 4 and 24 h intervals, in H460 cells for 72 h. The average
CI values are the mean of 0.5, 0.75, 0.90 and 0.95 FA. Values are
means ± SEM of at least 3 separate experiments.
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Figure 2 Cell cycle distribution – time curve for gemcitabine (closed
symbols) and paclitaxel (open symbols) alone at 10 × IC-50 concentration in
H460 NSCLC cells. The percentage of cells in the G0/G1 (triangles), S
(squares) and G2/M phases (circles) of the cell cycle are mean values of 3 or
4 experiments with SEM ≤ 28 of the mean
Table 3 Effect of gemcitabine–paclitaxel sequences on cell cycle distribution in H460 cells
Drugs Cell cycle phase 28 h 48 h 72 h
Gem + Tax G0/G1 38 ± 9✣ 46 ± 0.7 62 ± 0.5
S 26 ± 5✣ 28 ± 0.8 24 ± 0.7
G2/M 37 ± 4✣ 26 ± 0.1 15 ± 1
Gem > 4 h > Tax G0/G1 33 ± 5 49 ± 3  57 ± 6#
S 28 ± 2 30 ± 3 27 ± 4
G2/M 40 ± 4 21 ± 1  16 ± 3# 
Gem > 24 h > Tax G0/G1 25 ± 5# 40 ± 4  61 ± 5# 
S 40 ± 2 34 ± 7 26 ± 2 
G2/M 35 ± 4 29 ± 3 13 ± 3# †
Tax > 4 h > Gem G0/G1 38 ± 4 48 ± 3 45 ± 5
S 37 ± 8 30 ± 3 33 ± 3
G2/M 28 ± 4 22 ± 1 23 ± 3
Tax > 24 h > Gem G0/G1 48 ± 4* 50 ± 4 43 ± 6*
S 30 ± 2* 28 ± 2 34 ± 3*
G2/M 23 ± 4* 22 ± 3* 25 ± 3
Cell cycle distributions in H460 cells exposed to gemcitabine (Gem) simultaneously and 4 and 24 h prior to paclitaxel
(Tax) and the reverse sequences at IC-50 concentrations, as determined by FACS analysis using PI staining.
Cultures were incubated up to ✣ 24 (simultaneous), 28, 48 and 72 h. The cell cycle distribution at 0 h was as follows:
G1/G0: 41 ± 3, S: 30 ± 5, G2/M: 29 ± 4. Values are means ± SEM of 3 experiments. *Significantly different from the
reverse sequence (P < 0.05). #Significantly different from untreated cells (P < 0.05).  Significantly different from 28
hr (P < 0.03). †Significantly different from 48 hr (P = 0.01).gemcitabine (Table 4). At 1.0 µ M gemcitabine dFdCTP accumula-
tion was 370 ± 87 pmol/106 cells, but 0.3 µ M paclitaxel only
moderately increased dFdCTP accumulation to 429 ± 78 pmol/106
cells. In H322 cells, dFdCTP accumulation at 0.1 and 1.0 µ M
gemcitabine was 67 ± 5 and 462 ± 55 pmol/106 cells, but pacli-
taxel did not increase dFdCTP accumulation.
Increased dFdCTP accumulation might be related to altered
metabolism of cofactors involved in the synthesis of dFdCTP, such
as ATP and UTP, cofactors in gemcitabine phosphorylation, while
CTP and UTP may also regulate dCK (Ruiz van Haperen et al,
1996). In the NSCLC cells all ribonucleotide levels clearly
increased after gemcitabine alone and the gemcitabine-paclitaxel
combination (Table 4), in accordance with the results previously
obtained in vitro and in patients (Kroep et al, 1999; Van Moorsel et
al, 2000). In H322 cells the increase for all ribonucleotides was
less pronounced, maximal 1.8 fold.
In order to determine a possible role of dCK in the increased
dFdCTP accumulation, dCK activity was measured after 24 h
incubation with or without paclitaxel (IC-50) in the H460 and
H322 cell lines. No differences in dCK activity were found
between exposed and non-exposed cells. Furthermore, in H460
and H322 control cells, the dCK activities were similar, 0.8 ± 0.1
and 0.7 ± 0.1 nmol/h/106 (mean ± SEM), respectively.
Gemcitabine incorporation into DNA and RNA
The action of gemcitabine is dependent on its incorporation into
DNA and possibly into RNA, resulting in inhibition of nucleic
acid synthesis. We determined whether paclitaxel affected the
gemcitabine incorporation into DNA and RNA and its influence
on inhibition of DNA and RNA synthesis in the H460 and H322
cell lines. Gemcitabine clearly inhibited the DNA synthesis after 4
and 24 h of drug exposure in H460 cells, while in H322 cells inhi-
bition was more pronounced (Table 5). Paclitaxel alone did not
inhibit the DNA synthesis after 4 h exposure, but after 24 h expo-
sure a moderate inhibition was observed. However, in both cell
lines the drug combination did not increase the inhibition of
nucleic acid synthesis after 4 and 24 h exposure, as compared to
gemcitabine alone (Table 5). The latter might explain the additive
effect of the gemcitabine and paclitaxel combination.
Gemcitabine incorporation into DNA and RNA was drug expo-
sure- and time-dependent (Table 6); gemcitabine incorporation
into DNA increased almost 2-fold after 24 h exposure, as
compared to 4 h. In both H460 and H322 cells, paclitaxel did not
affect the gemcitabine incorporation into DNA. Paclitaxel seemed
to stimulate the gemcitabine incorporation into RNA (Table 5),
especially in H460 cells. Overall, gemcitabine incorporation into
RNA was lower than that into DNA. Gemcitabine incorporation
into DNA was 2 fold higher in the most sensitive cell line H460 as
compared to H322.
DISCUSSION
Scheduling of treatment plays an important role in optimizing the
efficacy of a drug combination. In NSCLC cells, paclitaxel admin-
istration prior to gemcitabine induced a higher apoptotic index and
might therefore be more favourable than the reverse sequence.
Although the precise cell killing mechanisms of gemcitabine and
paclitaxel are still unresolved, apoptosis plays a role in cell death
for both agents (Huang and Plunkett, 1995; Jordan et al, 1996).
Apoptosis was more pronounced in the schedules in which pacli-
taxel preceded gemcitabine, which might be explained by direct
drug effects as well as downstream signalling effects. Paclitaxel
has a high apoptotic index (Fig. 3) (Jordan et al, 1996) as
Sequence dependent effect of paclitaxel 1073
British Journal of Cancer (2000) 83(8), 1069–1076 © 2000 Cancer Research Campaign
Table 4 Effect of gemcitabine and paclitaxel combinations on ribonucleotide levels in H460 NSCLC cells
Drug Ribonucleotides; relative to pretreatment levels
[mean ± SEM (P-value)]
CTP UTP ATP GTP
Gemcitabine 0.1 µ M 2.2 ± 0.4b 1.8 ± 0.3b 1.6 ± 0.3b 1.6 ± 0.3c
Gemcitabine 0.1 µ M 2.2 ± 0.3a 1.9 ± 0.3b 1.8 ± 0.2a 1.6 ± 0.1a
+ paclitaxel 0.03 µ M
Gemcitabine 1.0 µ M 2.0 ± 0.4 2.0 ± 0.5c 1.7 ± 0.3c 1.5 ± 0.2c
Gemcitabine 1.0 µ M 2.0 ± 0.5c 2.1 ± 0.5c 1.9 ± 0.5c 2.0 ± 0.4c
+ paclitaxel 0.3 µ M
Ribonucleotide levels were measured in H460 cells after 24 h exposure to gemcitabine plus or minus paclitaxel,
respectively. Pretreatment nucleotide levels were set at 1% for each experiment. Ribonucleotide levels
(mean ± SEM; pmol/106 cells) at t = 0 were as follows: CTP = 215 ± 74, UTP = 1058 ± 437, ATP = 1206 ± 547,
GTP = 443 ± 185. *Significantly different from gemcitabine alone (P = 0.020). a = P ≤ 0.001; b = P ≤ 0.01; c = P ≤ 0.05.
Figure 3 The percentage of apoptotic cells, defined as apoptotic index, for
the four schedules, gemcitabine (G) 4 and 24 h prior to paclitaxel (T) and
both reversed schedules, after 28 (solid bars), 48 (hatched bars) and 72 h
(double hatched bars) of incubation. Apoptosis (sub-G1 peak) was
determined by FACS analysis using PI staining. The apoptotic index of
gemcitabine alone was 3.3 ± 0.8, 1.9 ± 0.6 and 6.0 ± 1.3 after 28, 48 and
72 h, respectively; the apoptotic index of paclitaxel 6.8 ± 3.1, 10.7 ± 4.2 and
15.8 ± 2.9, respectively. Values are means ± SEM of 3 experiments
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28 h 48 h 72 hcompared to gemcitabine, explaining the more pronounced
apoptosis when paclitaxel is administered first and thus for a
longer time. The increase in apoptosis may be related to increased
dFdCTP levels, since dFdCTP causes a (deoxy)ribonucleotide
pool imbalance and thereby contributes to induction of apoptosis
(Plunkett and Huang, 1995; Van Moorsel et al, 2000). Moreover,
the observed sequence dependent cell cycle distribution at 72 h
may play a role; the difference in G2/M to G1/S ratio at the 24 h
interval or the downstream factors directing the cells to G1/S or
G2/M arrest. There is not yet sufficient evidence to conclude
whether the assessment of apoptotic index is of prognostic value,
but with some drugs, such as topotecan or paclitaxel, apoptosis
appeared to correlate with the initial clinical response (Seiter et al,
1995).
Although the sequence paclitaxel before gemcitabine seemed
more favourable, growth inhibition of the combination was not
more than additive, irrespective of treatment schedule. This is in
partial agreement with data of Theodossiou et al (1998), who
found a less than additive effect when both agents were incubated
simultaneously or sequentially in human lung, breast and pancre-
atic cancer cell lines. This might be related to the different effects
on cell cycle distribution. Cells delayed by gemcitabine in G1/S
phase cannot proceed through the cell cycle and will be less sensi-
tive for the cytotoxic effects of paclitaxel. On the other hand, treat-
ment with paclitaxel will first induce a G2/M block, which might
decrease the gemcitabine effect. In addition, the lack of interaction
between both agents at the DNA level might explain the no more
than additive effect.
Mechanistic studies concentrated on gemcitabine metabolism,
with emphasis on dFdCTP accumulation and gemcitabine incor-
poration into DNA and RNA. In accordance with the results
obtained in patients (Kroep et al, 1999), paclitaxel increased
dFdCTP accumulation in H460 cells. To get a better understanding
of the mechanism for this phenomenon the influence on dCK and
ribonucleotide levels was also studied. dCK can be activated by
various genotoxic agents (Sasvari-Szekely et al, 1998, 1999), but
in NSCLC cells paclitaxel failed to show a direct effect on dCK
activity. However, the increased ribonucleotide levels in H460
cells might have contributed to gemcitabine phosphorylation,
while the lower increase in H322 cells might explain the lack of
increased dFdCTP levels. Despite the dFdCTP increase in H460
cells, paclitaxel did not influence the incorporation of gemcitabine
into DNA of these cells or that of H322 cells. Interestingly, pacli-
taxel seemed to increase gemcitabine incorporation into RNA,
although it is not clear how this relates to an increased apoptotic
index. However, for another fluoropyrimidine, 5-fluorouracil, its
incorporation into RNA was previously shown to be related to the
extent of apoptosis (Pritchard et al, 1997). The extent of gem-
citabine incorporation into DNA was related to the gemcitabine
sensitivity, since DNA incorporation was higher in the most sensi-
tive cell line H460.
In phase II trials in patients with NSCLC the combination of
gemcitabine and paclitaxel appeared to be well-tolerated, with
response rates ranging from 29% to 58% (Dombernowsky et al,
1998; Giaccone et al, 2000). Paclitaxel and gemcitabine have
been evaluated in a phase I study using a biweekly schedule
(Rothenberg et al, 1998), in which high doses of gemcitabine
(3000 mg/m2) could be given. However, the once weekly schedule
of gemcitabine (800–1500 mg/m2) administered as a 30 min infu-
sion is generally accepted as the most active one. In combination,
gemcitabine is usually preceded by paclitaxel as a 3 h infusion
once (175–200 mg/m2) or weekly (100–150 mg/m2). The weekly
administration of both drugs might enhance a potentiating interac-
tion. Gemcitabine has also been given before paclitaxel (Pedersen,
1997), but our data support the more generally used paclitaxel
before gemcitabine sequence. This combination is currently being
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Table 6 Effect of paclitaxel on gemcitabine incorporation into DNA and RNA of NSCLC cell lines
Incorporation into DNA Incorporation into RNA
Cell line Incubation (h) Gem alone Gem + Tax Gem alone Gem + Tax
H460 4 33.3 ± 0.4 34.9 ± 5.9 3.4 ± 3.7 3.2 ± 5.6
24 51.3 ± 13.3 42.6 ± 7.3 0.0 ± 0.0 12.1 ± 9.3
H322 4 14.8 ± 5.8 13.3 ± 4.3 0.0 ± 0.0 0.0 ± 0.0
24 29.0 ± 11.2 33.4 ± 11.2 0.4 ± 0.5 2.4 ± 3.7
H460 and H322 cells were exposed to 0.05 µ M gemcitabine alone, or in combination with 0.15 µ M paclitaxel, for 4
and 24 h. Values (fmol gemcitabine/106 cells) are means ± SEM of three separate experiments.
Table 5 Inhibition of DNA and RNA synthesis by gemcitabine, paclitaxel and the combination in H460 and H322 cells
DNA synthesis (%) RNA synthesis (%)
Cell Incubation
line (h) Gem Tax Gem + Tax Gem Tax Gem + Tax
H460 4 30 ± 4 115 ± 12 28 ± 9 62 ± 10 124 ± 4 67 ± 6
24 15 ± 3 61 ± 25 17 ± 4 70 ± 1 83 ± 14 73 ± 4
H322 4 20 ± 11 147 ± 5 21 ± 12 79 ± 18 110 ± 2 82 ± 17
24 11 ± 1 94 ± 3 15 ± 2 90 ± 28 134 ± 35 96 ± 29
The NSCLC cell lines H460 and H322 were exposed to 0.05 µ M gemcitabine (Gem) alone, or in combination with 0.15 µ M paclitaxel (Tax), for 4 and 
24 h. The effect of the drugs on both DNA and RNA synthesis is given as percentage of TdR and UR incorporation without drugs. For H460 cells TdR
incorporation without drugs at the end of the 4 and 24 h incubation was 41.4 ± 3 and 32.3 ± 5.9 pmol/106 cells, respectively; UR incorporation: 1.1 ± 0.1
and 0.75 ± 0.4 nmol/106 cells, respectively. For H322 cells TdR incorporation without drugs at the end of the 4 and 24 h incubation was 14.3 ± 4.7 and
23.1 ± 4.0 pmol/106 cells, respectively; UR incorporation: 0.59 ± 0.4 and 0.52 ± 0.1 nmol/106 cells, respectively. Values are means ± SEM of three
separate experiments.compared in an ongoing randomized EORTC trial with the
cisplatin-gemcitabine and the cisplatin-paclitaxel combinations.
In conclusion, although in vitro various schedules showed
similar cytotoxicity, paclitaxel administration prior to gemcitabine
seems to be favourable, because of the observed increased
dFdCTP accumulation, gemcitabine incorporation into RNA and
apoptotic index. Results of clinical studies may potentially be
affected by the sequence in which these drugs are administered.
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